Google
ATRA — ATARA BIOTHERAPEUTICS INC (Healthcare >> Biotechnology)
ATRA FAQ
What is ATRA's P/E ratio?
ATARA BIOTHERAPEUTICS INC (ATRA) currently trades at a P/E ratio of 37.94.
What is ATRA's ROE?
ATARA BIOTHERAPEUTICS INC reports a Return on Equity (ROE) of 25.37%.
What is ATRA's dividend yield?
ATARA BIOTHERAPEUTICS INC offers a dividend yield of 0.00%.
What is ATRA's Deepscope Quality Score?
Deepscope rates ATRA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ATRA?
Deepscope's AI Timing Score for ATRA is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ATRA belong to?
ATARA BIOTHERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.92
Price
-0.35
(-3.41%)
Day Change
|
|
|---|
ATRA, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 73 |
| Magic Formula Rank by ROA |
1002
|
| Magic Formula Rank by ROE |
1002
|
| Magic Formula Rank by ROIC |
998
|
| Price | 9.92 |
| PBV / Sector |
-2.43 / 4.63
|
| Earning Per Share | -1.04 |
| PE / Sector |
37.94 / 17.43
|
| PEG or PE/Growth / Sector |
-0.60 / 0.53
|
| Average 1M Daily Value |
3.66 M
GREAT
|
| Average 1W Daily Value |
0.83 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:38 |
| Symbol | ATRA |
| Name | ATARA BIOTHERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.01 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 90.55 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320
Phone: 805 623 4211
Website: https://www.atarabio.com
Sector: Healthcare >> Biotechnology
Description: Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
